Awareness of chronic kidney disease (CKD) and uptake of evidence-based interventions (EBIs) that increase awareness and/or slow progression to kidney failure remain alarmingly low. The global rise ...
Cystatin C is emphasized as a preferred biomarker for accurate GFR measurement in CKD assessment. SGLT2i are recommended for CKD patients, regardless of diabetes status, for kidney and ...
Updates on chronic kidney disease (CKD) diagnosis, use of sodium–glucose cotransporter-2 (SGLT-2) inhibitors as first-line therapy, and personalized treatment approaches for kidney and ...
Considering taking supplements to treat chronic kidney disease ckd? Below is a list of common natural remedies used to treat or reduce the symptoms of chronic kidney disease ckd. Follow the links ...
Assessment of proteinuria in addition to estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease (CKD) may help identify individuals at high risk of adverse outcomes ...
Chronic Kidney Disease (CKD) indicates prolonged kidney damage over three months, often undetectable until significant harm occurs. Key risk factors include diabetes, high blood pressure ...
Q4 2024 Management View CEO John Tucker highlighted FUROSCIX's Q4 2024 net revenue of $12.2 million, which aligns with the previously announced range of $12 million to $12.3 million. For the full year ...
GlobalData on MSN12d
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKDThe Furoscix 80 mg/10 ml subcutaneous injection is intended for oedema in adult CKD patients, including those with nephrotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback